Has Parth Desai, MD received payments from drug or device companies?

Yes. Drug and device makers reported $4,578 in general payments to Parth Desai, MD across 17 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Parth Desai, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Parth Desai, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Parth Desai, MD

Hematology & Oncology · Philadelphia, PANPI 1184074171

Payments from drug & device makers

$4,578in general payments, 2019–2025

Across 17 payments — averaging $269.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Rigel Pharmaceuticals, Inc.$2K
Merck$2K
Abbott$137
Boston Scientific$102
Johnson & Johnson$87
Daiichi Sankyo Inc.$44
plus $72 from 3 others

What the payments were for

Consulting fees$1,85541%
Speaking & faculty fees$1,75538%
Travel & lodging$3949%
Food & beverage$57413%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Rigel Pharmaceuticals, Inc.	4	$2,282
Merck	1	$1,855
Abbott	4	$137
Boston Scientific	1	$102
Johnson & Johnson	2	$87
Daiichi Sankyo Inc.	2	$44
Caris MPI, Inc.	1	$27
Jazz Pharmaceuticals Inc.	1	$26
Ardelyx, Inc.	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

GAVRETO$2,149
ACQUIRE$102

How this compares

$4,578 in reported general payments places this provider in the 50th percentile of 682 hematology & oncology providers in Pennsylvania.

See all hematology & oncology providers in Pennsylvania →

Medicare billing

Part B allowed, 2024

$7,917

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Mesalamine	14	$11,931
Oxycodone Hcl	28	$972
Ondansetron Hcl	22	$440
Prochlorperazine Maleate	22	$296

Paid to pharmacies, not to this prescriber.

Other hematology & oncology in Philadelphia

Stephen BagleyPhiladelphia$13.1M
Stephen SchusterPhiladelphia$9.5M
Pooja GhataliaPhiladelphia$8.3M
Corey LangerPhiladelphia$7.7M
Alfred GarfallPhiladelphia$7.6M
Charu AggarwalPhiladelphia$7M
Marcela MausPhiladelphia$4.4M
Catherine LaiPhiladelphia$3.8M
James StevensonPhiladelphia$3.4M
Tara MitchellPhiladelphia$3.2M

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →